Ellagic acid in multiple sclerosis
- Conditions
- Multiple Sclerosis.Multiple sclerosis
- Registration Number
- IRCT20120415009472N22
- Lead Sponsor
- Iran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 46
Patient informed consent
Disease diagnosis based on McDonald's criteria and MRI by a neurologist
EDSS score less than 5.5
Relapsing-remitting status of the disease
age between 18 and 55 years
Reluctance to participate in the study
Take nutritional supplements, antioxidants, and ellagic acid during a month before the start of the study and during the study (except for routine supplements that are part of the treatment plan for all patients, including vitamin D)
Taking nonsteroidal anti-inflammatory drugs, estrogen, progesterone, immunosuppressives, diuretics, and corticosteroids during a month before the study
Patients with inflammatory bowel disease (IBD), rheumatoid arthritis, systemic lupus erythematosus, type 1 diabetes, and other autoimmune diseases are excluded from the study.
Pregnancy and lactation
Drug abuse
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Expanded Disability Status Scale. Timepoint: At the beginning of the study and 12 weeks after supplementation with ellagic acid. Method of measurement: Extensive Disability Scale Questionnaire.
- Secondary Outcome Measures
Name Time Method